Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up productionEli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.{}

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.https://www.cnbc.com/2026/09/21/lilly-is-ramping-up-future-manufacturing-for-foundayo-obesity-pill.html